Loading…
BioCryst Pharmaceuticals, Inc. is projected to rise to $11.50 by 2027, a +26% move from its current price of $9.12. BCRX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $8.86 | $9.12 | $9.39 | +0.02% |
| May 30 | $8.76 | $9.12 | $9.51 | +0.05% |
| May 31 | $8.68 | $9.13 | $9.60 | +0.07% |
| Jun 1 | $8.61 | $9.13 | $9.67 | +0.09% |
| Jun 2 | $8.56 | $9.13 | $9.74 | +0.12% |
| Jun 3 | $8.51 | $9.13 | $9.81 | +0.14% |
| Jun 4 | $8.46 | $9.14 | $9.86 | +0.17% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $8.46 | $9.14 | $9.86 | +0.17% |
| Week 2 | $8.21 | $9.15 | $10.20 | +0.33% |
| Week 3 | $8.02 | $9.17 | $10.47 | +0.50% |
| Week 4 | $7.87 | $9.18 | $10.70 | +0.67% |
| Week 5 | $7.75 | $9.20 | $10.92 | +0.83% |
| Week 6 | $7.63 | $9.21 | $11.12 | +1.00% |
| Week 7 | $7.53 | $9.23 | $11.31 | +1.17% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
BioCryst Pharmaceuticals, Inc. is a healthcare company in the biotechnology sector focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases.
The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial.
The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc.
was founded in 1986 and is headquartered in Durham, North Carolina.
BioCryst Pharmaceuticals, Inc. (BCRX) operates in the Healthcare sector. The current price is $9.12, and the market capitalization is $2.32B. The company ranks 1893 in market value.
The price outlook provided in the year-by-year forecast shows a neutral stance for 2026 with an average price of $9.12 and a range of $6.24 to $12.55, implying no immediate return in that year.
From 2027 onward, the forecast shifts bullish, with rising averages through 2035 and into 2040 and 2050. For 2027 the average is $11.50, increasing to 2030 average $15.43, 2040 average $52.48, and 2050 average $90.78, with corresponding ROIs rising from 26.1 to 69.2, 475.5, and 895.4, respectively, and a bullish sentiment across these years.
A major floor 31.6% below — a decisive break under it would weaken the trend.
The nearest floor, 9.1% below — buyers have tended to step in here.
The nearest ceiling, 5.3% above — a clean break opens room to run.
A major ceiling 13.1% above — clearing it would confirm fresh momentum.
Key BCRX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BCRX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $8.60 | Buy | $8.74 | Buy |
| MA 10 | $8.89 | Buy | $8.78 | Buy |
| MA 20 | $8.91 | Buy | $8.87 | Buy |
| MA 50 | $9.19 | Sell | $8.85 | Buy |
| MA 100 | $8.28 | Buy | $8.54 | Buy |
| MA 200 | $7.92 | Buy | $8.27 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 53.46 | Neutral |
| Stoch RSI (14) | 70.35 | Neutral |
| CCI (20) | 50.85 | Neutral |
| Williams %R (14) | -36.64 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | 5.80 | Buy |
| Bollinger %B (20,2) | 0.65 | Neutral |
| Stochastic %K (14) | 63.36 | Neutral |
| TRIX (15) | -0.15 | Sell |
| Awesome (5,34) | -0.44 | Sell |
| Ultimate (7,14,28) | 52.53 | Neutral |
| Momentum (10) | 0.32 | Buy |
| Aroon Osc (25) | -28.00 | Sell |
| Hull MA (9) | 8.43 | Buy |
| ADX (14) | 13.15 | Neutral |
| ATR (14) | 0.23 | Info |
The 30-day technical picture remains constructive with bullish sentiment overall. RSI14 is 50, indicating a balanced near-term momentum.
The stock trades near the SMA50 of $9.19 and well above the SMA200 of $7.92, implying a positive longer-term trend. Support sits at $8.29 and resistance at $9.60, with a 30-day price range of $7.53 to $11.04.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $6.24 | $9.12 | $12.55 | 0% | Neutral | |
| $9.07 | $11.50 | $15.49 | +26% | Bullish | |
| $9.77 | $12.77 | $17.85 | +40% | Bullish | |
| $10.71 | $14.33 | $20.64 | +57% | Bullish | |
| $11.28 | $15.43 | $22.79 | +69% | Bullish | |
| $12.43 | $17.34 | $26.18 | +90% | Bullish | |
| $16.55 | $23.52 | $36.22 | +158% | Bullish | |
| $18.33 | $26.50 | $41.55 | +191% | Bullish | |
| $18.66 | $27.43 | $43.71 | +201% | Bullish | |
| $20.73 | $30.96 | $50.09 | +239% | Bullish | |
| $32.68 | $52.48 | $90.55 | +475% | Bullish | |
| $49.84 | $90.78 | $171.90 | +895% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $6.24 | $9.12 | $10.73 | +0.00% |
| June 2026 | $7.76 | $9.12 | $10.99 | +0.01% |
| July 2026 | $7.85 | $9.32 | $11.39 | +2.18% |
| August 2026 | $8.13 | $9.72 | $12.01 | +4.29% |
| September 2026 | $8.08 | $9.71 | $12.11 | -0.05% |
| October 2026 | $7.87 | $9.52 | $11.96 | -2.05% |
| November 2026 | $7.97 | $9.67 | $12.25 | +1.68% |
| December 2026 | $8.08 | $9.85 | $12.55 | +1.82% |
Click any year to see its month-by-month BCRX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, BCRX could reach as high as $12.55, with a base case around $9.12 and support toward $6.24 — roughly 0% from $9.12. Price action looks broadly range-bound.
Expect BCRX to range from $9.07 to $15.49 through 2027. The $11.50 average target implies a +26% move from current prices. That is up +26% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The BCRX price prediction for 2028 points to an average of $12.77 (low $9.77, high $17.85) — a potential gain of +40% on today's $9.12. Momentum favours further upside here.
In 2029, BCRX is projected to trade between $10.71 and $20.64, averaging $14.33 — a potential gain of +57% from today's $9.12. That is up +12% on the projected 2028 average. Buyers look set to stay in control over this stretch.
BioCryst Pharmaceuticals, Inc.'s 2030 outlook centres on $15.43, within a $11.28 to $22.79 range. That is up +8% on the projected 2029 average. That marks a +69% change versus current levels. Momentum favours further upside here.
By 2031, BCRX could reach as high as $26.18, with a base case around $17.34 and support toward $12.43 — roughly +90% from $9.12. Buyers look set to stay in control over this stretch.
Expect BCRX to range from $16.55 to $36.22 through 2032. The $23.52 average target implies a +158% move from current prices. That is up +36% on the projected 2031 average. Momentum favours further upside here.
The BCRX price prediction for 2033 points to an average of $26.50 (low $18.33, high $41.55) — a potential gain of +191% on today's $9.12. Buyers look set to stay in control over this stretch.
In 2034, BCRX is projected to trade between $18.66 and $43.71, averaging $27.43 — a potential gain of +201% from today's $9.12. That is up +3% on the projected 2033 average. Momentum favours further upside here.
BioCryst Pharmaceuticals, Inc.'s 2035 outlook centres on $30.96, within a $20.73 to $50.09 range. That is up +13% on the projected 2034 average. That marks a +239% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, BCRX could reach as high as $90.55, with a base case around $52.48 and support toward $32.68 — roughly +475% from $9.12. Momentum favours further upside here.
Expect BCRX to range from $49.84 to $171.90 through 2050. The $90.78 average target implies a +895% move from current prices. That is up +73% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in BCRX today (≈ 109.649123 BCRX) could be worth
$9,953.51
+$8,953.51 (+895%) by 2050 · US Dollar
Based on the average projected BCRX price of $90.78 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BCRXwould be worth at today's price.
$1,000 invested in BCRX on May 27, 2025 (≈ 92.678406 BCRX) would be worth
$845.23
-$154.77 (-15.5%) today · 0.85× · US Dollar
Based on a BCRX entry price of $10.79 vs. today's $9.12.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $8.74 | $1,043.48 | +4.3% |
| 1 month ago | $8.9 | $1,024.72 | +2.5% |
| 3 months ago | $7.9 | $1,154.43 | +15.4% |
| 6 months ago | $7.18 | $1,270.2 | +27.0% |
| 1 year ago | $10.79 | $845.23 | -15.5% |
| All time (5.0y) ago | $15.95 | $571.79 | -42.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BCRX forecast.
Our base-case forecast reaches $18.00 around 2032.
Implied market cap at $18.00: $4.57B
The multi-year forecast shows a bullish trajectory with rising average price and expanding upside across decades. For 2030, the average price is $15.43 with a min of $11.28 and a max of $22.79, and an ROI of 69.2, while 2040 projects an average price of $52.48 with a max of $90.55 and an ROI of 475.5, and 2050 shows an average price of $90.78 with a max of $171.90 and an ROI of 895.4. The 2035 forecast sits at an average of $30.96 with a max of $50.09 and an ROI of 239.4, continuing the bullish stance.
These figures indicate meaningful upside if conditions materialize, but they are estimates, not guarantees, and actual results can vary. The sentiment is bullish across these years.
Tap a question to reveal the answer.
In 2030 the forecast shows an average price of $15.43, a min of $11.28 and a max of $22.79, with a ROI of 69.2 and a bullish sentiment.
The forecast turns bullish from 2027 onward, with 2027 average $11.50 and rising to 2030 average $15.43; ROI grows to 69.2 by 2030 and 895.4 by 2050, with bullish sentiment in the later years.
2035 is forecast to have a max of $50.09, with an average of $30.96 and a ROI of 239.4, and a bullish sentiment.
The current price is $9.12 and the market cap is $2.32B.
For 2040 the average price is $52.48, with a min of $32.68 and a max of $90.55, ROI 475.5, and bullish sentiment.
BioCryst Pharmaceuticals, Inc. Community Discussion
0Share your BioCryst Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.